Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 608951, 9 pages
Review Article

Regulatory T Cells in Allogeneic Stem Cell Transplantation

1Hematology Division & Bone Marrow Transplantation, Chaim Sheba Medical Center, Sackler Medical School, Tel Aviv University, Tel Aviv 52621, Israel
2Hematology Division & Cord Blood Bank, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv 52621, Israel

Received 26 March 2013; Accepted 15 April 2013

Academic Editor: Nicolaus Kroger

Copyright © 2013 Maria Michael et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Growing evidence suggests that cellular adoptive immunotherapy is becoming an attractive though challenging approach in regulating tumor immunity and alloresponses in clinical transplantation. Naturally arising CD4+CD25+Foxp3+ regulatory T cells (Treg) have emerged as a key component in this regard. Over the last decade, a large body of evidence from preclinical models has demonstrated their crucial role in auto- and tumor immunity and has opened the door to their “first-in-man” clinical application. Initial studies in clinical allogeneic stem cell transplantation are very encouraging and may pave the way for other applications. Further improvements in Treg ex vivo or in vivo expansion technologies will simplify their global clinical application. In this review, we discuss the current knowledge of Treg biology and their potential for cell-based immunotherapy in allogeneic stem cell transplantation.